A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phas...

Full description

Bibliographic Details
Main Authors: Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt, Lilli Podola, Tobias Friedrich, Heinz Lubenau, Marco Springer, Sébastien Wieckowski, Klaus M. Breiner, Gerd Mikus, Markus W. Büchler, Anne-Valerie Keller, Ruhan Koc, Christoph Springfeld, Phillip Knebel, Mariana Bucur, Lars Grenacher, Walter E. Haefeli, Philipp Beckhove
Format: Article
Language:English
Published: Taylor & Francis Group 2018-04-01
Series:OncoImmunology
Subjects:
anti-angiogenesis
immune-oncology
human cd8+ t cells
oral vaccination
pancreatic cancer
salmonella typhi
vegfr2
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1303584

Internet

http://dx.doi.org/10.1080/2162402X.2017.1303584

Similar Items